info@aurevixpeptides.com
EspañolRead references
Illustrative vial: CJC-1295 + Ipamorelin BlendCJC-1295 + Ipamorelin Blend

Illustrative presentation

INFORMATIONAL REFERENCE

CJC-1295 + Ipamorelin Blend

This combination brings together CJC-1295 Without DAC, Ipamorelin. Explore each component’s research focus below, followed by the evidence for the combination.

Research focus & potential applications

CJC-1295 Without DAC

This entry concerns GHRH-related signaling without the DAC modification. Understanding the precise molecule matters because published long-acting CJC-1295 results cannot be transferred directly to the non-DAC form.

Ipamorelin

Ipamorelin is investigated for ghrelin-receptor activity, growth-hormone release and gastrointestinal function. These are distinct research areas; the postoperative trial discussed below did not establish its primary recovery benefit.

What the research shows

Explore the selected studies, their findings and their limits.

CJC-1295 Without DAC

Read the findings & sourcesIdentity or formulation distinction

This name is commonly used for a modified GHRH fragment lacking the albumin-binding DAC group. The frequently cited CJC-1295 human study tested the long-acting DAC form, so its duration and hormone results cannot be assigned to this entry. A verified sequence and a study of the matching molecule are needed before describing formulation-specific outcomes.

Ipamorelin

Read the findings & sourcesHuman study discussed

Ipamorelin has been investigated as a growth-hormone secretagogue and for bowel recovery after surgery. In a randomized postoperative study, the primary comparison for recovery of gastrointestinal function was not statistically significant. A proposed mechanism or hormone response therefore should not be presented as demonstrated recovery, sleep or body-composition benefit.

Evidence for the combination

The sources above examine individual constituents or related molecules. They do not test this exact combination. A combined effect, improved recovery or greater safety cannot be inferred by adding the individual findings together.

For more information, contact info@aurevixpeptides.com.

Editorial review: September 23, 2026